SG Americas Securities LLC Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

SG Americas Securities LLC increased its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 18.2% during the first quarter, HoldingsChannel.com reports. The fund owned 640,179 shares of the company’s stock after buying an additional 98,783 shares during the period. SG Americas Securities LLC’s holdings in Kiniksa Pharmaceuticals International were worth $30,825,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Amundi acquired a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after purchasing an additional 1,002 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Creative Planning purchased a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $358,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the sale, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This represents a 47.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the sale, the director owned 12,546 shares in the company, valued at approximately $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 653,301 shares of company stock valued at $34,046,073. 51.98% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals International Trading Up 4.1%

KNSA opened at $59.49 on Wednesday. The stock’s 50-day moving average price is $51.46 and its 200 day moving average price is $46.63. Kiniksa Pharmaceuticals International, plc has a 12-month low of $26.27 and a 12-month high of $59.94. The firm has a market cap of $4.58 billion, a price-to-earnings ratio of 66.10 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.Kiniksa Pharmaceuticals International’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.11 EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Citigroup upped their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, June 8th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Finally, Jefferies Financial Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $60.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.